In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

New Products In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Bausch & Lomb's Stellaris PC: Company debuts its Stellaris PC (Procedural Choice) vision enhancement system overseas following CE mark approval last May. The combined vitrectomy and phacoemulsification system, for which a May 510(k) submission remains pending at FDA, enhances surgeons' ability to see ocular tissue under various surgical conditions, B&L claims. Stellaris PC is indicated for emulsification and removal of cataracts, and anterior and posterior segment vitrectomy

You may also be interested in...



Perseon Cancer Ablation Therapy Expanded To Treat Liver Tumors

The newly renamed company says FDA has cleared its MicroThermX microwave ablation system to treat complicated non-resectable liver tumors.

Financings In Brief

EnteroMedics plans secondary offering

Financings In Brief

EnteroMedics plans secondary offering

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

See All
UsernamePublicRestriction

Register

MT029289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By